glp 1 is produced by GLP-1 Receptor Agonist Services for Type 2 Diabetes and Obesity Drug Development GLP-1 Genetics: How Genes Affect

Approved injection sites: Abdomen (except 2 inches around navel), thigh (front and outer), back of upper arm

2014) and pro-oxidant properties (Linetsky et al

Monitoring recommendations: Baseline investigations: Full blood count, B12 level, folate, and intrinsic factor antibodies (if pernicious anaemia suspected) During initial treatment: Potassium monitoring in severe deficiency (risk of hypokalaemia) Follow-up: Repeat full blood count after 8 weeks to confirm haematological response Long-term: Annual review to ensure compliance with maintenance injections

However, its worth noting that doses above 3 grams per day produce more serious side effects [15]

The standard eligibility criteria for prescribing tirzepatide are as follows: Body mass index (BMI) of 30 or greater, or